Legal & General Group
PRVB

Legal & General Group’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

Legal & General Group’s Portfolio PRVB Stock Details PRVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-39,941
Closed -$963K – 3611
2023
Q1 		$963K Buy
39,941
+11,787
+42% +$148K ﹤0.01% 2167
2022
Q4 		$298K Buy
28,154
+7,143
+34% +$57.6K ﹤0.01% 2470
2022
Q3 		$95K Sell
21,011
-14,335
-41% -$65.3K ﹤0.01% 2841
2022
Q2 		$141K Buy
35,346
+2,983
+9% +$14.1K ﹤0.01% 2757
2022
Q1 		$237K Hold
32,363
– – ﹤0.01% 2610
2021
Q4 		$182K Buy
32,363
+17,178
+113% +$109K ﹤0.01% 2760
2021
Q3 		$97K Buy
15,185
+9,394
+162% +$60.4K ﹤0.01% 2857
2021
Q2 		$49K Sell
5,791
-1,418
-20% -$11.4K ﹤0.01% 2960
2021
Q1 		$76K Buy
7,209
+100
+1% +$1.41K ﹤0.01% 2698
2020
Q4 		$120K Hold
7,109
– – ﹤0.01% 2536
2020
Q3 		$91K Sell
7,109
-1,306
-16% -$16.5K ﹤0.01% 2518
2020
Q2 		$119K Buy
+8,415
New +$106K ﹤0.01% 2485

Other funds holding PRVB

UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Legal & General Group's PRVB Position: Q2 2023 in Review

Legal & General Group sold out of Provention Bio, Inc. Common Stock (PRVB) in Q2 2023, closing a stake of 39,941 shares — an estimated $963K sold.

Legal & General Group first reported a position in PRVB in Q2 2020 and held it in 12 quarters. The position peaked at $963K in Q1 2023. 1 fund tracked by Wall St. Rank holds PRVB as of Q2 2023.

  • Legal & General Group reported no remaining Provention Bio, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Legal & General Group sold 39,941 Provention Bio, Inc. Common Stock shares in Q2 2023, an estimated $963K.
  • Legal & General Group first reported a position in Provention Bio, Inc. Common Stock in Q2 2020 and held it in 12 quarters.
  • Legal & General Group's Provention Bio, Inc. Common Stock position peaked at $963K in Q1 2023.
  • 1 fund tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q2 2023.

Based on Legal & General Group's 13F filing for Q2 2023, filed 14 Aug 2023.